ABSTRACT
Eighty-eight dogs with relapsed lymphoma were treated with the MOMP (mechlorethamine, vincristine, melphalan and prednisone) protocol on a 28-day treatment cycle. The overall response rate (ORR) to the MOMP protocol was 51.1% for a median of 56 days (range 7-858 days). Twelve percent of dogs experienced a complete response for a median of 81 days (range 42-274 days) and 38.6% experienced a partial response for a median of 49 days (range 7-858 days). Dogs with T-cell lymphoma had an ORR of 55% for a median of 60 days (range 49-858 days) while those with B-cell lymphoma had an ORR of 57% for a median of 81 days (range 7-274 days) (P = 0.783). The overall survival time for all dogs was 183 days (range 17-974 days). Fifty-four percent of dogs experienced toxicity with the majority classified as grade I. The MOMP protocol seems well-tolerated and is an option for dogs with relapsed lymphoma.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Dog Diseases/drug therapy , Lymphoma/veterinary , Mechlorethamine/administration & dosage , Melphalan/administration & dosage , Prednisone/administration & dosage , Vincristine/administration & dosage , Animals , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Dog Diseases/mortality , Dogs , Female , Lymphoma/drug therapy , Lymphoma/mortality , Lymphoma, B-Cell/drug therapy , Lymphoma, B-Cell/mortality , Lymphoma, B-Cell/veterinary , Lymphoma, T-Cell/drug therapy , Lymphoma, T-Cell/mortality , Lymphoma, T-Cell/veterinary , Male , Mechlorethamine/therapeutic use , Melphalan/therapeutic use , Prednisone/therapeutic use , Recurrence , Survival Analysis , Vincristine/therapeutic useABSTRACT
Masitinib mesylate is a tyrosine kinase inhibitor approved for the treatment of gross, non-metastatic grade II and III canine mast cell tumours (MCTs). This study evaluated the use of masitinib as a frontline and rescue agent for metastatic and non-metastatic canine MCTs. Identification of toxicities and prognostic factors in these dogs was of secondary interest. Twenty-six dogs were included in this study. The overall response rate to masitinib was 50%. The median survival time for dogs that responded to masitinib was 630 days versus 137 days for dogs that did not respond (P = 0.0033). Toxicity was recorded in 61.5% of treated dogs, but the majority of adverse events were mild and self-limiting. Response to masitinib, not tumour grade, stage or location, was the most significant prognostic factor for survival in dogs with MCTs.
Subject(s)
Dog Diseases/drug therapy , Mastocytosis, Cutaneous/veterinary , Protein Kinase Inhibitors/therapeutic use , Skin Neoplasms/veterinary , Thiazoles/therapeutic use , Animals , Benzamides , Disease-Free Survival , Dogs , Female , Kaplan-Meier Estimate , Male , Mastocytosis, Cutaneous/drug therapy , Neoplasm Staging , Piperidines , Protein Kinase Inhibitors/pharmacology , Pyridines , Schools, Veterinary , Skin Neoplasms/drug therapy , Tennessee , Thiazoles/pharmacologyABSTRACT
Performance and clinical characteristics of a novel hyperthermia antenna operating at 434 MHz were evaluated for the adjuvant treatment of locally advanced superficial tumours in cats, dogs and horses. Electromagnetic simulations were performed to determine electric field characteristics and compared to simulations for a flat microwave antenna with similar dimensions. Simulation results show a reduced skin surface and backfield irradiation and improved directional irradiation (at broadside) compared to a flat antenna. Radiated power and penetration is notably increased with a penetration depth of 4.59 cm compared to 2.74 cm for the flat antenna. Clinical use of the antenna was then evaluated in six animals with locoregionally advanced solid tumours receiving adjuvant chemotherapy. During clinical applications, therapeutic temperatures were achieved at depths ≥4 cm. Objective responses were seen in all patients; tissue toxicity in one case limited further therapy. This antenna provides compact, efficient, focused and deep-penetrating clinical hyperthermia for the treatment of solid tumours in veterinary patients.
Subject(s)
Cat Diseases/therapy , Dog Diseases/therapy , Horse Diseases/therapy , Hyperthermia, Induced/veterinary , Neoplasms/veterinary , Animals , Cats , Dogs , Equipment Design , Horses , Hyperthermia, Induced/instrumentation , Hyperthermia, Induced/methods , Neoplasms/therapy , Pilot ProjectsABSTRACT
A carcinoma ex pleomorphic adenoma was diagnosed in the left mandibular salivary gland of an 8-year-old female spayed dog. The animal presented with a large nonpainful swelling in the left submandibular region. A computed tomography scan detected an irregularly enhancing soft tissue mass that was closely associated with the left external ear canal and extended to the left wing of the atlas. On surgical exploration, the mass was intimately associated with the left mandibular salivary gland. Both the mass and the adjacent gland were removed, and the diagnosis was determined by histopathology. The tumor was comprised of basaloid and low columnar epithelial cells, many glandular units formed by well-differentiated sebocytes, and multifocal regions of necrosis, mineralization, and hemorrhage. Salivary gland tumors with sebaceous differentiation are very rare in animals, with one previously reported case in a cat.